In a report issued on March 6, Taylor Feehley from Chardan Capital maintained a Buy rating on Seres Therapeutics (MCRB), with a price target of $15. The company’s shares closed on Friday at $5.11, close to its 52-week low of $4.42.
According to TipRanks.com, Feehley is ranked #3516 out of 5218 analysts.
Currently, the analyst consensus on Seres Therapeutics is a Strong Buy with an average price target of $14, which is a 174.0% upside from current levels. In a report issued on February 22, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $16 price target.
See today’s analyst top recommended stocks >>
Based on Seres Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $21.29 million. In comparison, last year the company had a GAAP net loss of $28.95 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seres Therapeutics, Inc. is a microbiome therapeutics platform company, which engages in the development of biological drugs. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
